Core Viewpoint - Chengdu Yuandong Pharmaceutical Co., Ltd. has participated in the continuation procurement of drugs whose agreements have expired under the national organization procurement program, with 13 products proposed for selection in this round [1][2]. Group 1: Proposed Selected Products - The proposed selected products include 12 that were previously selected in the first to eighth batches of the national organization procurement, and one new product, Paricalcitol Injection [2]. - The total expected sales revenue from these products is approximately 651.20 million yuan for 2024, accounting for 48.25% of the company's total revenue for that year [2]. - For the first nine months of 2025, the expected sales revenue is about 504.08 million yuan, representing 49.46% of the company's total revenue for that period [2]. Group 2: Impact on the Company - The procurement cycle for these selected products will run from the actual execution date of the selection results until December 31, 2028, with medical institutions prioritizing the use of these selected drugs [2]. - The overall procurement is expected to maintain price stability or further decline, providing medical institutions with greater choice and ensuring continuity in clinical medication [2]. - Although some selected products may see a decrease in price compared to previous sales, having 13 products proposed for selection allows the company to solidify its market share and enhance the accessibility of these drugs [2].

Core Viewpoint - The company, Yuandong Biotech (688513.SH), has participated in the procurement process for the continuation of drug products after the expiration of the national organized procurement agreements, with 13 products, including Bisoprolol Fumarate Tablets and Etoricoxib Tablets, proposed for selection in this procurement [1] Group 1 - The procurement process is led by Jiangsu, Henan, and Guangdong provinces, aiming to stabilize or further reduce prices while providing greater choice for medical institutions [1] - The selection of products allows medical institutions to choose suppliers with better supply assurance capabilities, thereby ensuring continuity in clinical medication and reducing the risks associated with drug switching due to centralized procurement [1] - Although some selected products have lower prices compared to previous sales, the selection of 13 products positions the company to maintain its market share and enhance the accessibility of these drugs if contracts are signed and executed [1]

Core Viewpoint - Yuan Dong Biotech (688513.SH) has participated in the procurement process for the continuation of drug selection following the expiration of the national organized procurement agreements, with 13 products, including Fumarate Bisoprolol Tablets and Etoricoxib Tablets, proposed for selection in this round of procurement [1] Group 1 - The procurement process is organized by Jiangsu, Henan, and Guangdong provinces, aiming to stabilize or further reduce drug prices while providing greater choice for medical institutions [1] - The selection of 13 products by the company, despite some price reductions compared to original sales prices, is expected to help maintain market share and enhance drug accessibility if contracts are signed and executed [1] - The procurement aims to ensure continuity in clinical medication and reduce the risks associated with drug switching due to organized procurement [1]

Group 1 - Unisplendour Corporation has decided to terminate its plan to issue H-shares and list on the Hong Kong Stock Exchange due to strategic development considerations [2] - Yuandong Biotech is participating in a follow-up procurement for 13 products, with expected sales revenue of approximately 651 million yuan in 2024, accounting for 48.25% of total revenue [3] - Blue Lithium has terminated its participation in the GreenMei Indonesia project due to strategic adjustments by GreenMei, with no significant impact on its operations [4] Group 2 - Jinhaitong plans to invest up to 400 million yuan in the construction of a semiconductor equipment manufacturing center in Shanghai, covering an area of 55,000 square meters [5] - Kaiying Network's subsidiary has signed a settlement agreement with Legend IP, which is expected to positively impact profits by approximately 200 million yuan [6] - Newray plans to acquire 70% of PCB tool company Huilian Electronics for no more than 700 million yuan, enhancing its market position in the PCB tool sector [7] Group 3 - Longbai Group intends to acquire a 5.46% stake in Yunnan Guotai for 234 million yuan [8] - Dawi Technology's Zhangbei data center project is set to be completed by October 2025, primarily providing customized standard data center environments [9] Group 4 - Guobang Electronics reported a net profit of 508 million yuan for 2025, a year-on-year increase of 4.72%, despite a revenue decline of 7.92% [11] - Daotong Technology achieved a net profit of 935 million yuan in 2025, reflecting a significant year-on-year growth of 45.89% [12] - Jingchen Co. reported a net profit of 871 million yuan for 2025, with a growth of 6% year-on-year [13] Group 5 - Qizhou Dongfeng plans to repurchase shares worth between 50 million and 100 million yuan to implement an employee stock ownership plan [17] - Keri Technology's shareholders plan to reduce their holdings by a total of up to 3.13% of the company's shares [19] Group 6 - Roman Co. signed a 260 million yuan contract for a wind power project, with the company’s share of the contract amounting to approximately 190 million yuan [21] - Zhongke Haixun is expected to win projects totaling approximately 288 million yuan [22] - Shan Jian Co. won four construction projects with a total value of 4.834 billion yuan [23]

Core Viewpoint - The company, Yuandong Biotech (688513.SH), has participated in the procurement process for the continuation of drugs whose agreements from the national centralized procurement have expired, with 13 products proposed for selection in this round [1][2]. Group 1: Procurement Details - The company has submitted applications for the continuation procurement organized by Jiangsu, Henan, and Guangdong provinces [1]. - The proposed selected products include 12 that were previously selected in the first to eighth batches of national centralized procurement and one new product, Paricalcitol Injection [1]. - The sales revenue from these products is projected to be approximately 651.20 million yuan in 2024, accounting for 48.25% of the company's total revenue for that year [1]. Group 2: Impact on Revenue - For the period from January to September 2025, the expected sales revenue from these products is about 504.08 million yuan, representing 49.46% of the company's total revenue for that period [1]. - The procurement cycle will last until December 31, 2028, during which medical institutions will prioritize the selected drugs, ensuring the completion of agreed procurement volumes [2]. Group 3: Market Stability - The overall pricing of the procurement is expected to remain stable or decrease further, providing medical institutions with greater choice and ensuring continuity in clinical medication [2]. - Although some selected products may see a price decrease compared to original sales prices, the selection of 13 products allows the company to maintain its market share and enhance the accessibility of these drugs [2].

Core Viewpoint - The application for Fumaric Acid Bisoprolol Tablets by Merck Healthcare Germany GmbH has been accepted by the National Medical Products Administration of China, indicating a significant step in the drug's market entry process [1] Group 1: Application Details - The application acceptance date is December 13, 2025 [1] - The application number for the drug is JYHZ2500291 [1] - The drug type is classified as a chemical drug and the application type is for import re-registration [1] Group 2: Company Information - The applicant company is Merck Healthcare Germany GmbH, which is part of the larger Merck Group, including Merck Healthcare KGaA and Merck Serono Co. Ltd. [1]

Core Viewpoint - The announcement indicates that the company's wholly-owned subsidiary, Four Ring Pharmaceutical, has had several of its products included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025), which may influence future sales but will not significantly impact the company's current operating performance [1] Group 1: Product Inclusion - A total of 34 products from the company's subsidiaries, including Beijing Huasu, Shandong Huasu, and Duoduo Pharmaceutical, have been included in the 2025 drug catalog [1] - New products added to the catalog include Sulfate Fish Protein Injection and Compound Pancreatin Powder [1] - Products previously included in the 2024 catalog, such as Bisoprolol Fumarate Tablets and Benidipine Hydrochloride Tablets, will continue to be listed [1] Group 2: Product Changes - Beijing Huasu's "Compound Chlorphentermine Injection" has been removed from the 2025 catalog [1] - Duoduo Pharmaceutical's "Ambroxol Hydrochloride Injection" has been newly included in the catalog [1] Group 3: Market Impact - The future sales of the included products may be affected by changes in the market environment and other factors [1] - The company states that these changes will not have a major impact on its current operating performance [1]

Group 1 - Warner Pharmaceuticals received the drug registration certificate for polyethylene glycol sodium potassium powder, which is indicated for the treatment of chronic constipation and fecal impaction [1] - The approval of the drug registration certificate enriches the company's formulation product variety and positively impacts the optimization of the product structure [1] - Warner Pharmaceuticals reported a revenue of 714 million yuan for the first half of 2025, a year-on-year decrease of 3.37%, with a net profit attributable to shareholders of 71 million yuan, down 36.95% [1] Group 2 - Renfu Pharmaceutical announced that its subsidiary, Wuhan Jiulong Renfu Pharmaceutical Co., received the drug registration certificate for dapoxetine hydrochloride tablets, which are used to treat premature ejaculation [2] - The total sales of dapoxetine hydrochloride tablets in 2024 are estimated to be around 1.1 billion yuan, with major manufacturers including Shandong Huabo Kaisheng Biotechnology Co. and Sichuan Kelun Pharmaceutical Co. [2] - Anglikon received the drug registration certificate for azilsartan potassium tablets, which are indicated for the treatment of primary hypertension in adults [3] - Xinhua Pharmaceutical announced the approval of fumarate bisoprolol tablets, indicated for hypertension and chronic stable heart failure with reduced left ventricular function [3]

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the marketing of Fumarate Bisoprolol Tablets, which are indicated for hypertension, coronary heart disease (angina), and chronic stable heart failure with reduced left ventricular systolic function (ejection fraction ≤ 35%) [1] Summary by Category Product Approval - The approval includes the issuance of a Drug Registration Certificate for Fumarate Bisoprolol Tablets [1] - The product is intended for use under medical supervision alongside ACE inhibitors, diuretics, and selectively used cardiac glycosides [1] Indications - Fumarate Bisoprolol Tablets are indicated for the treatment of: - Hypertension - Coronary heart disease (angina) - Chronic stable heart failure with reduced left ventricular systolic function (ejection fraction ≤ 35%) [1]

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration certificate of Fumarate Bisoprolol Tablets, indicating a significant advancement in its product portfolio [1] Group 1: Product Approval - The Fumarate Bisoprolol Tablets are indicated for the treatment of hypertension and coronary heart disease (angina) [1] - The product is also indicated for chronic stable heart failure with reduced left ventricular systolic function (ejection fraction ≤ 35%) [1] - The use of this medication requires adherence to medical advice, including the use of ACE inhibitors, diuretics, and selectively using cardiac glycosides [1]